Literature DB >> 3754756

Pharmacokinetics of atracurium and its metabolites.

S Ward, B C Weatherley.   

Abstract

The pharmacokinetic profile of atracurium was studied in normal patients and in patients with renal failure, renal-hepatic failure, or hepatic disease. Its short elimination half-life was not significantly altered by renal failure, but in patients with severe liver disease elimination of its metabolites was prolonged, necessitating care during long-term i.v. infusions in patients with hepatic dysfunction.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3754756     DOI: 10.1093/bja/58.suppl_1.6s

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  9 in total

Review 1.  Clinical pharmacokinetics of the newer neuromuscular blocking drugs.

Authors:  D P Atherton; J M Hunter
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

2.  Quantitative determination of atracurium in human plasma using high-performance liquid chromatography.

Authors:  R Okutani; K Kono; F M DeBros; D M Philbin
Journal:  J Anesth       Date:  1988-09-01       Impact factor: 2.078

3.  Pharmacokinetics of atracurium besylate in the pig after a single i.v. injection.

Authors:  C Schopfer; J F Pittet; D R Morel; E Tassonyi; A Benakis
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1989 Oct-Dec       Impact factor: 2.441

Review 4.  Clinical pharmacokinetics of neuromuscular blocking drugs.

Authors:  S Agoston; R H Vandenbrom; J M Wierda
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

5.  Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function.

Authors:  R H Vandenbrom; J M Wierda; S Agoston
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

Review 6.  Pharmacokinetics of drugs used in critically ill adults.

Authors:  B M Power; A M Forbes; P V van Heerden; K F Ilett
Journal:  Clin Pharmacokinet       Date:  1998-01       Impact factor: 6.447

Review 7.  Cisatracurium besilate. A review of its pharmacology and clinical potential in anaesthetic practice.

Authors:  H M Bryson; D Faulds
Journal:  Drugs       Date:  1997-05       Impact factor: 9.546

8.  Pharmacokinetic modelling of a parent drug and its metabolite. Atracurium and laudanosine.

Authors:  V Nigrovic; M Banoub
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

Review 9.  Adverse reactions and interactions of the neuromuscular blocking drugs.

Authors:  D Ostergaard; J Engbaek; J Viby-Mogensen
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Sep-Oct
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.